La Jolla Pharmaceutical Co LJPC:NASDAQ

Last Price$4.01NASDAQ Previous Close - Last Trade as of 4:00PM ET 5/13/22

Today's Change+0.04(1.01%)
Bid (Size)$3.75 (2)
Ask (Size)$4.60 (7)
Day Low / High$4.01 - 4.23
Volume44.6 K

View Biotechnology IndustryPeer Comparison as of 05/13/2022


La Jolla Pharmaceutical Co ( NASDAQ )

Price: $4.01
Change: +0.04 (1.01%)
Volume: 44.6 K
4:00PM ET 5/13/2022

Cortexyme Inc ( NASDAQ )

Price: $3.38
Change: +0.02 (0.60%)
Volume: 312.2 K
4:00PM ET 5/13/2022

Anixa Biosciences Inc ( NASDAQ )

Price: $3.37
Change: +0.17 (5.31%)
Volume: 47.0 K
3:59PM ET 5/13/2022

Champions Oncology Inc ( NASDAQ )

Price: $7.48
Change: +0.10 (1.36%)
Volume: 2.0 K
3:59PM ET 5/13/2022

Brainstorm Cell Therapeutics Inc ( NASDAQ )

Price: $2.72
Change: +0.01 (0.37%)
Volume: 99.6 K
4:00PM ET 5/13/2022

Read more news Recent News

-- Earnings Flash (LJPC) LA JOLLA PHARMACEUTICAL COMPANY Posts Q4 Revenue $75.7M
8:17AM ET 3/09/2022 MT Newswires


Insider Sell: La Jolla Pharmaceutical
6:22AM ET 12/02/2021 MT Newswires

Kevin C Tang, 10% Owner, Director, on November 29, 2021, sold 441,290 shares in La Jolla Pharmaceutical (LJPC) for $1,734,150. Following the Form 4 filing...

La Jolla Pharmaceutical Launches $10 Million Share Buyback Plan
11:12AM ET 11/17/2021 MT Newswires

La Jolla Pharmaceutical (LJPC) said Wednesday it has launched a share buyback program of up to $10 million. Repurchases can be made from time to time and...

-- Earnings Flash (LJPC) LA JOLLA PHARMACEUTICAL COMPANY Posts Q3 Revenue $13.3M
8:51AM ET 11/04/2021 MT Newswires


View all Commentary and Analysis

Marinus Pharmaceuticals (MRNS) Reports Q1 Loss, Tops Revenue Estimates
4:35PM ET 5/12/2022 Zacks

Marinus Pharmaceuticals (MRNS) delivered earnings and revenue surprises of 40.23% and 548.36%,...

Our Take On La Jolla Pharmaceutical Company
2:06PM ET 7/02/2021 Seeking Alpha

Company Profile

Business DescriptionLa Jolla Pharmaceutical Co. operates as a biopharmaceutical company. It engages in the discovery, development and commercialization of therapies intended to improve outcomes in patients suffering from life-threatening diseases. Its products portfolio include GIAPREZA and XERAVA. The company was founded in 1989 and is headquartered in San Diego, CA. View company web site for more details
Address201 Jones Road
Waltham, Massachusetts 02451
Number of Employees169
Recent SEC Filing05/03/20224
President, Chief Executive Officer & DirectorLarry G. Edwards
Senior Vice President-Pharmaceutical OperationsLuke Seikkula
Chief Financial Officer & SecretaryMichael S. Hearne
Chief Medical OfficerTony Hodges

Company Highlights

Price Open$4.05
Previous Close$4.01
52 Week Range$3.35 - 5.69
Market Capitalization$102.7 M
Shares Outstanding25.6 M
SectorHealth Technology
Next Earnings Announcement05/13/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / Earnings7.04
Earnings per Share$0.56
Beta vs. S&P 500N/A
Revenue$10.1 M
Net Profit Margin25.96%
Return on Equity-28.61%

Analyst Ratings as of 03/11/2022

Consensus RecommendationConsensus Icon
Powered by Factset